Inhibition of HERV expression by treatment with the BTK inhibitor (ibrutinib) led to over 50% survival in the CLL model, suggesting that aberrantly regulated HERVs may be involved in CLL pathogenesis (42). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.